Annals of Hematology

, Volume 92, Issue 5, pp 707–709 | Cite as

Erythroleukemia showing early erythroid and cytogenetic responses to azacitidine therapy

  • Sho Hangai
  • Fumihiko Nakamura
  • Yasuhiko Kamikubo
  • Akira Honda
  • Shunya Arai
  • Masahiro Nakagawa
  • Motoshi Ichikawa
  • Mineo Kurokawa
Letter to the Editor

References

  1. 1.
    Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK (2010) Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol 89(9):841–850PubMedCrossRefGoogle Scholar
  2. 2.
    Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, Gore SD, Ramos F, Beyne-Rauzy O, List A, McKenzie D, Backstrom J, Beach CL (2010) Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 149(2):244–249PubMedCrossRefGoogle Scholar
  3. 3.
    Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569PubMedCrossRefGoogle Scholar
  4. 4.
    Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257(4):2041–2048PubMedGoogle Scholar
  5. 5.
    Gambari R, del Senno L, Barbieri R, Viola L, Tripodi M, Raschellà G, Fantoni A (1984) Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine. Cell Differ 14(2):87–97PubMedCrossRefGoogle Scholar
  6. 6.
    Lowrey CH, Nienhuis AW (1993) Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. N Engl J Med 329(12):845–848PubMedCrossRefGoogle Scholar
  7. 7.
    Charache S, Dover G, Smith K, Talbot CC, Moyer M, Boyer S (1983) Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci U S A 80(15):4842–4846PubMedCrossRefGoogle Scholar
  8. 8.
    Vigil C, Cortes J, Kantarjian HM, Garcia-Manero G, Lancet JE, List AF (2009) Hypomethylating therapy for the treatment of acute erythroleukemia patients. Blood (ASH Ann Meet Abstr) 114:2069Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Sho Hangai
    • 1
  • Fumihiko Nakamura
    • 1
  • Yasuhiko Kamikubo
    • 1
  • Akira Honda
    • 1
  • Shunya Arai
    • 1
  • Masahiro Nakagawa
    • 1
  • Motoshi Ichikawa
    • 1
  • Mineo Kurokawa
    • 1
    • 2
  1. 1.Department of Hematology and Oncology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of Cell Therapy and TransplantationThe University of Tokyo HospitalTokyoJapan

Personalised recommendations